Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.

13 Although differences in response at the same threshold were seen for patients with STS, the difference did not reach statistical significance, potentially due to the limited number of patients and the more modest effect size in patients with STS compared to mRCC, 13 therefore, although less robust, the same threshold might be applicable for patients with STS. 13 Not only survival but also response rates (assessed using the RECIST crite

also in 111,027 other papers